Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459673) titled 'HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Breast Cancer
HER2-positive Breast Cancer
Breast Cancer Stage IV
Intervention:
Diagnostic Test: Personalis NeXT Personal
Diagnostic Test: Natera Signatera
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: March 4, 2026
...